Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL. Abraham SA, et al. Among authors: scott mt. Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8. Nature. 2016. PMID: 27281222 Free PMC article.
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL, Vetrie D. Scott MT, et al. Cancer Discov. 2016 Nov;6(11):1248-1257. doi: 10.1158/2159-8290.CD-16-0263. Epub 2016 Sep 14. Cancer Discov. 2016. PMID: 27630125 Free PMC article.
hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.
Pellicano F, Park L, Hopcroft LEM, Shah MM, Jackson L, Scott MT, Clarke CJ, Sinclair A, Abraham SA, Hair A, Helgason GV, Aspinall-O'Dea M, Bhatia R, Leone G, Kranc KR, Whetton AD, Holyoake TL. Pellicano F, et al. Among authors: scott mt. Blood. 2018 Apr 5;131(14):1532-1544. doi: 10.1182/blood-2017-05-783845. Epub 2018 Feb 5. Blood. 2018. PMID: 29437554 Free PMC article.
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
Baquero P, Dawson A, Mukhopadhyay A, Kuntz EM, Mitchell R, Olivares O, Ianniciello A, Scott MT, Dunn K, Nicastri MC, Winkler JD, Michie AM, Ryan KM, Halsey C, Gottlieb E, Keaney EP, Murphy LO, Amaravadi RK, Holyoake TL, Helgason GV. Baquero P, et al. Among authors: scott mt. Leukemia. 2019 Apr;33(4):981-994. doi: 10.1038/s41375-018-0252-4. Epub 2018 Sep 5. Leukemia. 2019. PMID: 30185934 Free PMC article.
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML.
Bugler J, Kinstrie R, Scott MT, Vetrie D. Bugler J, et al. Among authors: scott mt. Front Cell Dev Biol. 2019 Jul 17;7:136. doi: 10.3389/fcell.2019.00136. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31380371 Free PMC article. Review.
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. Kinstrie R, et al. Among authors: scott mt. Leukemia. 2020 Jun;34(6):1613-1625. doi: 10.1038/s41375-019-0684-5. Epub 2020 Jan 2. Leukemia. 2020. PMID: 31896780 Free PMC article.
Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. Kinstrie R, et al. Among authors: scott mt. Leukemia. 2020 Jul;34(7):1975. doi: 10.1038/s41375-020-0721-4. Leukemia. 2020. PMID: 32005922 Free PMC article.
94 results